Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GEN3014 |
Synonyms | |
Therapy Description |
GEN3014 (Hexabody-CD38) is a modified human monoclonal antibody against CD38 that may enhance complement dependent cytotoxicity against tumor cells (Blood (2019) 134 (Supplement_1): 3106). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GEN3014 | Hexabody-CD38|GEN 3014|GEN 3014 | CD38 Antibody 20 | GEN3014 (Hexabody-CD38) is a modified human monoclonal antibody against CD38 that may enhance complement dependent cytotoxicity against tumor cells (Blood (2019) 134 (Supplement_1): 3106). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04824794 | Phase Ib/II | GEN3014 | GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies | Active, not recruiting | USA | SWE | POL | NZL | NLD | HUN | GRC | FRA | ESP | DNK | CZE | AUS | 8 |